Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Q1 2025 Earnings Presentation
15 slides from Staar Surgical's earnings presentation, May 7, 2025
Slide 1: First Quarter 2025 Earnings Call and Webcast Presentation
NASDAQ: STAA First Quarter 2025 Earnings Call and Webcast Presentation MAY 7, 2025 Addressing the myopia epidemic as the global leader in phakic IOLs for vision correction Exhibit 99.2
Slide 2: Today's Speakers
STAAR Surgical Earnings Call and Webcast First Quarter 2025 STEPHEN FARRELL Chief Executive Officer WARREN FOUST DEBORAH ANDREWS President and Chief Operating Officer Interim Chief Financial Officer Today’s Speakers 02 Webcast participants may also email questions for today’s Q&A Session to ir@staar
Slide 3: Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 193
Slide 4: Non-GAAP Financial Information
Non-GAAP Financial Information To supplement the Company’s financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), this presentation and the accompanying tables include certain non-GAAP financial measures, including Adjusted EBITDA. Management uses these
Slide 5: STAAR Surgical + EVO ICL Around the World
STAAR Surgical + EVO ICL™ Around the World FIRST QUARTER 2025 05
Slide 6: STAAR Surgical Is Turning the Corner
06 STAAR Surgical Is Turning the Corner STEPHEN FARRELL Chief Executive Officer First Quarter 2025 01 02 03 04 Q1’25 sales results were in-line with expectations, but we can and will do better China in-market demand is getting stronger $42.6M Q1’25 Net Sales -45% Y/Y vs. $77.4M in Q1’24 Q1’25 Net Sa
Slide 7: Mitigating China Tariffs, Swiss Manufacturing and EVO+ (V5)
07 Mitigating China Tariffs, Swiss Manufacturing and EVO+ (V5) WARREN FOUST President and Chief Operating Officer First Quarter 2025 Inspiring surgeon clinical and economic confidence that leads to a mindset and approach to drive consistent conversions to EVO ICL - already prevalent in Asia Advancin
Slide 8: Financial Overview
08 Financial Overview DEBORAH ANDREWS Interim Chief Financial Officer First Quarter 2025 Adjusted EBITDA 1 Restructuring, Impairment and Related Charges $22.7M Adjusted EBITDA per share 1 Dollars in millions Net Sales 1 Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP financial measures. F
Slide 9: Regional Sales Performance
09 Notes: Americas includes the United States, Canada and Latin American countries; EMEA includes Spain, Germany, United Kingdom, European, Middle East and Africa Distributors; APAC includes China, Japan, South Korea, India and the rest of Asia Pacific distributors. Americas EMEA APAC Ex. China GLOB
Slide 10: Gross Margin, Cash, and Restructuring, Impairment and Related Charges
Gross Margin, Cash, and Restructuring, Impairment and Related Charges First Quarter 2025 Gross Margin ~70% 75%-80% 2H25 Gross margin temporarily depressed due to Switzerland manufacturing ramp and increased reserves for excess and obsolete inventory. $22.7 Million on Q1’25 Income Statement Restructu
Slide 11: Withdrawing Outlook; Return to Profitability
11 Withdrawing Outlook; Return to Profitability First Quarter 2025 The Company announced that it is withdrawing the financial outlook previously provided on February 11, 2025. Withdrawing Guidance Proprietary Collamer® Material 30+ years Market Leadership and Experience Proven Clinical Outcomes The
Slide 12: Very Large and Growing Global Myopia Market
12 Very Large and Growing Global Myopia Market STAAR Surgical 2.7B People, All Ages 1.1B People, Ages 21-45 IMMEDIATE TARGET MARKET We believe the benefits of our EVO ICL technology make it the clear choice for refractive vision correction as it has already become in markets like Japan. High Surgeon
Slide 13: First Quarter 2025 Earnings Call and Webcast Q&A
13 STAAR SURGICAL FIRST QUARTER 2025 EARNINGS CALL AND WEBCAST Q&A
Slide 14: Sales by Region and Country
14 FISCAL YEAR THREE MONTHS ENDED Sales by Region 2022 2023 2024 Mar 29, 2024 Jun 28, 2024 Sep 27, 2024 Dec 27, 2024 Mar 28, 2025 Americas(1) 19,798 22,315 25,229 6,157 6,656 6,029 6,387 6,739 EMEA(2) 40,733 39,488 44,073 11,202 10,235 9,760 12,876 12,331 APAC (3) 223,860 260,612 244,599 59,997 82,1
Slide 15: Net Income (Loss) to Adjusted EBITDA
15 Net Income (Loss) to Adjusted EBITDA (in 000's except for per share data) 2022 Q1-23 Q2-23 Q3-23 Q4-23 2023 Q1-24 Q2-24 Q3-24 Q4-24 2024 Q1-25 Net income (loss) (as reported) $39,665 $2,710 $6,064 $4,817 $7,756 $21,347 $(3,339) $7,379 $9,980 $(34,228) $(20,208) $(54,211) Provision (benefit) for i